That peanuts are synonymous with air travel is a fact that most travellers don’t give a second thought to. But for travellers with severe food allergies, this airline tradition poses a significant risk for their ability to fly comfortably, or at all.
It is not just peanuts. There are myriad allergens—dairy, shellfish, or tree nuts, to name a few—that allergy sufferers may unwittingly encounter in-flight. This can come in the form of accidental consumption of an allergen, cross-contamination with residue from a former passenger—ground-up nuts on the floor or in the seat for example, or Dorito dust on the tray table or, in some rarer cases, even airborne transmission from an in-flight meal that is being served.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.